Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Price, Quote, News and Overview

NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD

13.48  +0.06 (+0.45%)

DNLI Quote, Performance and Key Statistics

DENALI THERAPEUTICS INC

NASDAQ:DNLI (5/27/2025, 1:59:23 PM)

13.48

+0.06 (+0.45%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High33.33
52 Week Low10.57
Market Cap1.96B
Shares145.28M
Float130.84M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30
IPO12-08 2017-12-08


DNLI short term performance overview.The bars show the price performance of DNLI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

DNLI long term performance overview.The bars show the price performance of DNLI in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of DNLI is 13.48 USD. In the past month the price decreased by -14.41%. In the past year, price decreased by -30.14%.

DENALI THERAPEUTICS INC / DNLI Daily stock chart

DNLI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 327.86B
AMGN AMGEN INC 13.41 149.75B
GILD GILEAD SCIENCES INC 14.06 135.39B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.21B
REGN REGENERON PHARMACEUTICALS 13.68 65.46B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.23B
ARGX ARGENX SE - ADR 99.33 35.60B
ONC BEIGENE LTD-ADR 6.08 25.68B
BNTX BIONTECH SE-ADR N/A 23.80B
NTRA NATERA INC N/A 21.53B
SMMT SUMMIT THERAPEUTICS INC N/A 19.50B
BIIB BIOGEN INC 8.17 18.94B

About DNLI

Company Profile

DNLI logo image Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 422 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.

Company Info

DENALI THERAPEUTICS INC

161 Oyster Point Blvd.

South San Francisco CALIFORNIA 94080 US

CEO: Ryan J. Watts

Employees: 422

DNLI Company Website

DNLI Investor Relations

Phone: 16508668547

DENALI THERAPEUTICS INC / DNLI FAQ

What is the stock price of DENALI THERAPEUTICS INC today?

The current stock price of DNLI is 13.48 USD. The price increased by 0.45% in the last trading session.


What is the ticker symbol for DENALI THERAPEUTICS INC stock?

The exchange symbol of DENALI THERAPEUTICS INC is DNLI and it is listed on the Nasdaq exchange.


On which exchange is DNLI stock listed?

DNLI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for DENALI THERAPEUTICS INC stock?

25 analysts have analysed DNLI and the average price target is 38.54 USD. This implies a price increase of 185.92% is expected in the next year compared to the current price of 13.48. Check the DENALI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is DENALI THERAPEUTICS INC worth?

DENALI THERAPEUTICS INC (DNLI) has a market capitalization of 1.96B USD. This makes DNLI a Small Cap stock.


How many employees does DENALI THERAPEUTICS INC have?

DENALI THERAPEUTICS INC (DNLI) currently has 422 employees.


What are the support and resistance levels for DENALI THERAPEUTICS INC (DNLI) stock?

DENALI THERAPEUTICS INC (DNLI) has a resistance level at 13.78. Check the full technical report for a detailed analysis of DNLI support and resistance levels.


Is DENALI THERAPEUTICS INC (DNLI) expected to grow?

The Revenue of DENALI THERAPEUTICS INC (DNLI) is expected to grow by 260.05% in the next year. Check the estimates tab for more information on the DNLI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy DENALI THERAPEUTICS INC (DNLI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does DENALI THERAPEUTICS INC (DNLI) stock pay dividends?

DNLI does not pay a dividend.


When does DENALI THERAPEUTICS INC (DNLI) report earnings?

DENALI THERAPEUTICS INC (DNLI) will report earnings on 2025-07-30.


What is the Price/Earnings (PE) ratio of DENALI THERAPEUTICS INC (DNLI)?

DENALI THERAPEUTICS INC (DNLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.67).


What is the Short Interest ratio of DENALI THERAPEUTICS INC (DNLI) stock?

The outstanding short interest for DENALI THERAPEUTICS INC (DNLI) is 8.94% of its float. Check the ownership tab for more information on the DNLI short interest.


DNLI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

DNLI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to DNLI. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DNLI Financial Highlights

Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS decreased by -151.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.77%
ROE -34.38%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-151.89%
Revenue 1Y (TTM)-100%

DNLI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to DNLI. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of -14.2% and a revenue growth 260.05% for DNLI


Ownership
Inst Owners91.51%
Ins Owners4.61%
Short Float %8.94%
Short Ratio7.62
Analysts
Analysts88
Price Target38.54 (185.91%)
EPS Next Y-14.2%
Revenue Next Year260.05%